| |
Breast
Cancer : What we know
Breast
cancer is the most
common cancer in women in the world, in both industrialized and
developing countries. In 1999, 467,000 women's deaths were attributed
to breast cancer (1.7% of all female deaths).
And
as the graph indicates, breast
cancer incidence rates are increasing in many countries,
although mortality rates are stable or slightly declining in some.
For
the vast majority of cases of breast cancer, however, we cannot
explain the causes.
We
know that a small percentage of cases are linked to an inherited
gene. Women who have inherited that gene within families that
carry it are more far likely to experience breast cancer. But we also
know that many more women without that gene type develop breast cancer
also.
One of the best established risk factors for breast cancer during middle age and beyond is life-time experience with estrogen. More estrogen increases breast cancer risk. Many factors influence this, including the levels of intrauterine estrogens during fetal development, whether or not a woman has born a child and if so, when (early or late) and whether or not she breastfed, when her menstrual periods started, when she entered into menopause, obesity, etc.
Other risk factors under consideration include diet, alcohol and solvents, radiation, electromagnetic fields, , unusual light cycles, smoking and soot.
The role of estrogen in breast cancer risk has raised the possibility that environmental contaminants that mimic estrogen might also be involved. The evidence on this remains inconclusive. Early studies with relatively small sample sizes indicated a positive association between several organochlorine compounds and breast cancer risk. More recent work has cast doubt on some of these findings. And the latest results indicate that there are links between some estrogenic compounds and breast cancer risk, for example diethylstilbestrol and dioxin.
|
As
this work has developed, additional complications have arisen.
While they limit what we can say based on current evidence, they provide
strong guidance for how future research can and must be conducted.
- First,
some of the compounds that had been thought to be estrogenic—to
bind with the estrogen receptor and activate genes that estrogen itself
would—are instead anti-androgenic or even anti-estrogenic
(they block action of androgens and estrogens, respectively).
This is the case for DDE (an especially persistent metabolite of DDT)
and some very persistent forms of PCBs. Thus a generation of epidemiological
work that intended to test the role of estrogenic organochlorines because
of the observation that estrogen itself elevates breast cancer risk
was misguided. Studies making this mistake continue to be done, nonetheless,
for example the Long Island Breast
Cancer Research Project. Based on this more recent understanding
of DDE's hormonal activity, we should not expect DDE to be associated
with an increase in breast cancer risk. DDT itself is another matter,
because DDT is a true estrogen.
- This
raises the second complication. Most of these studies have measured
breast cancer at the time of breast cancer diagnosis, or even later.
[That is one reason why DDE has been a focus: DDT is converted in the
body after exposure to several metabolites, of which one form of DDE,
p,p'-DDE, is the most persistent.] Yet research in the laboratory
with animals and epidemiological studies of women increasingly indicate
that the cellular events sowing the seeds for breast cancer take place
decades before breast cancer can be detected. It is very unlikely
that chemical measurements decades later accurately, or perhaps even
remotely, reflect conditions at the time when those cellular events
began. This is especially the case because while some estrogenic compounds
like dieldrin are persistent, others
like bisphenol A are not.
- The
third complication is that all these chemicals come in mixtures. The
presence of mixtures
weakens the power of epidemiology to find links between exposure
and disease quite dramatically. Real links can be there but be masked
by the complications caused by the presence of tens, if not hundreds,
of compounds.
What
do these complications mean for future research? First, a strong
emphasis should be placed on studies that can assess chemical exposures
during crucial periods of mammary gland development (especially in the
womb and around puberty) and examine the links between those exposures
and breast cancer risk much later in life. Second, at least for the "environmental
estrogen hypothesis," research should concentrate on compounds that
actually are estrogens. Third, epidemiological studies links between environmental
estrogens and breast cancer risk need to broaden their scope of inquiries
beyond the traditionally-studied persistent organochlorine compounds and
include nonpersistent estrogens like bisphenol A in their analyses. And
finally, new methods in epidemiology are urgently needed to cope with
the obstacles that mixtures pose for research.
Where
does that leave us now? Current scientific evidence does not
prove definitively that contaminants are involved in the causation of
breast cancer. They are implicated, nonetheless, and their involvement
is highly plausible, based on what we know from animal experiments, from
basic mechanisms in biology, and from well-designed epidemiological studies.
Stronger
evidence of links is emerging as the studies become more sophisticated
and explicitly incorporate methods that circumvent some of the complications
noted above. Less weight should be given to research that, by ignoring
those complications, has increased its vulnerability to what statisticians
call "false negatives" ... finding no statistical association
when there really was one.
Last
modified 20 October 2002
|